[Expression of RhoA and Rho kinase in junctional zone of human adenomyosis and its relationship with dysmenorrheal].
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
RhoA and Rho kinase expression in the adenomyosis junctional zone is elevated compared to controls, positively correlates with dysmenorrhea severity, and does not show cyclic changes.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To investigate the expression of RhoA and Rho kinase in junctional zone (JZ) of adenomyosis and normal myometrium and explore its relationship with severity of dysmenorrheal. METHODS: From Mar. to Dec. 2012, 32 cases with adenomyosis undergoing hysterectomy were enrolled as adenomyosis group including 18 cases with proliferative endometrium and 14 cases with secretory endometrium matched with 29 cases with hysterectomy due to cervical disease and ovarian tumor as control group including 12 cases with proliferative endometrium and 17 cases with secretory endometrium in Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University. JZ smooth muscle cells were isolated and cultured immediately after the operation. The expression of mRNA and protein of RhoA and ROCK1 in JZ in two groups were measured by real-time fluorescence quantitative RT-PCR and western blot. RESULTS: (1) The mRNA expression of RhoA and ROCK1 in JZ of adenomyosis group did not show cyclic change. In proliferative phase, the expression of RhoA and ROCK1 (1.41 ± 0.16, 1.05 ± 0.15) was not significantly higher than that in secretory phase (1.17 ± 0.25, 0.98 ± 0.10) (P > 0.05). While JZ in control group, it showed obviously cyclic change. The expression level of them in proliferative phase (0.93 ± 0.10, 1.00 ± 0.18) was significantly higher than that in secretory phase (0.48 ± 0.03, 0.55 ± 0.05) (P < 0.05); It also showed that expressions of RhoA and ROCK1 in adenomysis group were significant higher than those in the control (P < 0.05). (2) The mRNA and protein expression of RhoA and ROCK1 was positively correlated in each of two groups(r = 0.48, P < 0.01;r = 0.67, P < 0.01). (3)The expression of RhoA and ROCK1 were 1.66 ± 0.19, 1.32 ± 0.11 in severe dysmenorrheal, 1.28 ± 0.12, 1.09 ± 0.08 in moderate dysmenorrheal and 0.93 ± 0.09,0.81 ± 0.06 in mild dysmenorrheal, it all reached statistical difference when compared the other group. (All P < 0.05). CONCLUSIONS: The expressions of RhoA and ROCK1 in JZ in adenomyosis group were higher than those in control group, and positively correlated with the severity of dysmenorrheal in adenomysis group, but it does not change with the menstrual cycle. High expression of RhoA and ROCK1 might be involved in abnormal contraction of uterine myometrium and correlated with the dysmenorrheal in adenomysis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- 17β-Estradiol Induces Overproliferation in Adenomyotic Human Uterine Smooth Muscle Cells of the Junctional Zone Through Hyperactivation of the Estrogen Receptor-Enhanced RhoA/ROCK Signaling Pathway 2015
- RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis 2018
- Benign Uterine Diseases 2019
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
Cited by (4)
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
- Benign Uterine Diseases 2019
- RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis 2018
- 17β-Estradiol Induces Overproliferation in Adenomyotic Human Uterine Smooth Muscle Cells of the Junctional Zone Through Hyperactivation of the Estrogen Receptor-Enhanced RhoA/ROCK Signaling Pathway 2015
Source provenance
- europepmc
- last seen: 2026-08-11T06:11:44.160905+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:18:40.923139+00:00
License: CC0
· commercial use OK